X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1411) 1411
Publication (42) 42
Newsletter (32) 32
Book Review (17) 17
Newspaper Article (10) 10
Magazine Article (6) 6
Book Chapter (3) 3
Dissertation (2) 2
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (939) 939
insulin aspart (677) 677
insulin (625) 625
female (570) 570
endocrinology & metabolism (565) 565
index medicus (558) 558
male (541) 541
insulin - analogs & derivatives (503) 503
diabetes mellitus, type 2 - drug therapy (463) 463
hypoglycemic agents - therapeutic use (435) 435
diabetes (414) 414
middle aged (414) 414
type 2 diabetes (395) 395
hypoglycemic agents - administration & dosage (386) 386
insulin - therapeutic use (372) 372
aspart (347) 347
adult (345) 345
insulin - administration & dosage (337) 337
diabetes mellitus, type 1 - drug therapy (304) 304
glycemic control (291) 291
hypoglycemia (265) 265
aged (252) 252
blood glucose - metabolism (249) 249
therapy (245) 245
treatment outcome (233) 233
type 1 diabetes (228) 228
diabetes mellitus, type 2 - blood (220) 220
glucose (204) 204
glargine (198) 198
hypoglycemic agents - adverse effects (196) 196
mellitus (194) 194
research (184) 184
nph insulin (181) 181
blood glucose - drug effects (179) 179
insulin glargine (177) 177
diabetes therapy (175) 175
drug administration schedule (175) 175
lispro (165) 165
hyperglycemia (163) 163
insulin - adverse effects (163) 163
drug therapy (161) 161
glycated hemoglobin a - metabolism (157) 157
insulin detemir (157) 157
diabetes mellitus (154) 154
pharmacology & pharmacy (150) 150
management (144) 144
care and treatment (142) 142
insulin aspart - administration & dosage (142) 142
hypoglycemia - chemically induced (141) 141
insulin aspart - therapeutic use (141) 141
insulin lispro (139) 139
diabetes mellitus, type 1 - blood (137) 137
internal medicine (132) 132
medicine, general & internal (132) 132
dosage and administration (130) 130
glycated hemoglobin a - analysis (127) 127
adolescent (119) 119
insulin analogues (115) 115
insulin, long-acting (115) 115
hypoglycemic agents - pharmacokinetics (114) 114
type 2 diabetes mellitus (113) 113
cross-over studies (112) 112
blood glucose - analysis (111) 111
biphasic insulin aspart (109) 109
pharmacokinetics (109) 109
insulin, isophane (106) 106
insulin - pharmacokinetics (105) 105
biphasic insulins (104) 104
analog (102) 102
medicine & public health (100) 100
analysis (98) 98
open-label (97) 97
basal insulin (91) 91
drug therapy, combination (91) 91
blood sugar (90) 90
efficacy (90) 90
time factors (84) 84
trial (83) 83
clinical trials (81) 81
injections, subcutaneous (81) 81
insulin infusion systems (81) 81
quality of life (81) 81
detemir (80) 80
dextrose (80) 80
endocrine system diseases (80) 80
pregnancy (79) 79
insulin aspart - adverse effects (78) 78
safety (78) 78
complications (77) 77
health aspects (75) 75
insulin, long-acting - therapeutic use (75) 75
child (74) 74
medicine, research & experimental (74) 74
body mass index (73) 73
insulin, long-acting - administration & dosage (73) 73
nutritional and metabolic diseases (73) 73
biphasic insulin aspart 30 (71) 71
metformin (71) 71
risk factors (71) 71
postprandial period (70) 70
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1328) 1328
German (32) 32
Romanian (29) 29
Spanish (18) 18
Japanese (13) 13
French (12) 12
Chinese (8) 8
Hungarian (5) 5
Danish (3) 3
Polish (3) 3
Russian (3) 3
Czech (2) 2
Portuguese (2) 2
Turkish (2) 2
Italian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1489 - 1497
Journal Article
Diabetic Medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
Aims To assess resource utilization associated with severe hypoglycaemia across three insulin regimens in a large phase 3a clinical programme involving people... 
GLYCEMIC CONTROL | 26-WEEK | GLARGINE | NAIVE PATIENTS | ENDOCRINOLOGY & METABOLISM | NON-INFERIORITY TRIAL | OPEN-LABEL | TO-TARGET TRIAL | BASAL-BOLUS TREATMENT | TYPE-2 | DEGLUDEC/INSULIN ASPART | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Complications | Research
Journal Article
Drugs, ISSN 0012-6667, 7/2012, Volume 72, Issue 11, pp. 1495 - 1520
Biphasic insulin aspart 30 (BIAsp 30) includes 30% soluble rapid-acting insulin aspart (IAsp) along with an intermediate-acting 70% protaminated IAsp that... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Glimepiride | Hypoglycaemia | Pioglitazone | Insulin-aspartinsulin-protamine-aspart | Sitagliptin | Blood-glucose | Exenatide | Insulin-glulisine | Insulin-neutral-protamine-lisproinsulin- lispro | Sulfonylureas | Rosiglitazone | Diabetes-mellitus | Metformin | Glibenclamide | Insulin-detemir | Insulin-glargine | Thiazolidinediones | MULTIPLE DAILY INJECTIONS | COST-EFFECTIVENESS | IMPROVES GLYCEMIC CONTROL | BASAL INSULIN | MONOMERIC INSULINS | HUMAN PREMIX INSULIN | TYPE-2 DIABETES PATIENTS | TWICE-DAILY INJECTIONS | PHARMACOLOGY & PHARMACY | OPEN-LABEL | TOXICOLOGY | SUBGROUP ANALYSIS | Hypoglycemic Agents - therapeutic use | Insulin Aspart - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Biphasic Insulins - adverse effects | Humans | Insulin Aspart - pharmacokinetics | Insulin, Isophane - pharmacokinetics | Biphasic Insulins - pharmacokinetics | Hypoglycemic Agents - pharmacology | Biphasic Insulins - pharmacology | Insulin, Isophane - therapeutic use | Animals | Biphasic Insulins - therapeutic use | Insulin, Isophane - adverse effects | Insulin Aspart - pharmacology | Insulin, Isophane - pharmacology | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Pharmaceutical research | Insulin aspart | Clinical trials | Product development | Research | Pharmaceutical industry | Testing | Review
Journal Article
Journal Article
Drugs & Aging, ISSN 1170-229X, 1/2017, Volume 34, Issue 1, pp. 29 - 38
Due to population aging, an increasing number of elderly patients with diabetes use insulin. It is therefore important to investigate the characteristics of... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Geriatrics/Gerontology | YOUNGER ADULTS | PHARMACOLOGY & PHARMACY | GLYCEMIC CONTROL | THERAPY | ONSET | GERIATRICS & GERONTOLOGY | Insulin Aspart - therapeutic use | Insulin, Short-Acting - administration & dosage | Humans | Aging - drug effects | Insulin Aspart - pharmacokinetics | Male | Insulin Aspart - chemistry | Dose-Response Relationship, Drug | Young Adult | Insulin Aspart - administration & dosage | Hypoglycemic Agents - administration & dosage | Time Factors | Adult | Female | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Blood Glucose - analysis | Double-Blind Method | Treatment Outcome | Hypoglycemic Agents - chemistry | Chemistry, Pharmaceutical | Diabetes Mellitus, Type 1 - drug therapy | Aging - blood | Cross-Over Studies | Insulin, Short-Acting - chemistry | Diabetes Mellitus, Type 1 - blood | Adolescent | Insulin, Short-Acting - pharmacokinetics | Aged | Glucose Clamp Technique | Insulin, Short-Acting - therapeutic use | Usage | Care and treatment | Type 1 diabetes | Insulin aspart | Research | Pharmacokinetics | Drug therapy | Health aspects | Risk factors | FDA approval | Glucose | Hypoglycemia | Metabolism | Insulin | Studies | Older people | Aging | Population | Adults | Diabetes | Drug dosages | Age | Geriatrics | Original
Journal Article
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 3/2019, Volume 36, Issue 3, pp. 1 - 14
Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart containing two additional excipients: niacinamide, to increase early... 
Biochemistry, general | Biomedicine | oligomerization | absorption | fast-acting insulin aspart | vasodilation | Pharmacy | niacinamide | Medical Law | Pharmacology/Toxicology | Biomedical Engineering and Bioengineering | absorption; fast-acting insulin aspart; niacinamide; oligomerization; vasodilation | SUBCUTANEOUS INJECTION | GLYCEMIC CONTROL | PROFILES | HYDROTROPIC SOLUBILIZATION | NICOTINAMIDE | BLOOD-FLOW | CHEMISTRY, MULTIDISCIPLINARY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | ONSET | Hypoglycemic Agents - pharmacokinetics | Endothelial Cells - metabolism | Humans | Cells, Cultured | Insulin Aspart - pharmacokinetics | Scattering, Small Angle | Subcutaneous Absorption - drug effects | Diabetes Mellitus, Type 1 - drug therapy | Dose-Response Relationship, Drug | Insulin Aspart - administration & dosage | Animals | Regional Blood Flow - drug effects | Hypoglycemic Agents - administration & dosage | Models, Biological | X-Ray Diffraction | Diabetes Mellitus, Type 1 - blood | Injections, Subcutaneous | Subcutaneous Tissue - blood supply | Female | Niacinamide - pharmacology | Vasodilation - drug effects | Subcutaneous Tissue - metabolism | Sus scrofa | Subcutaneous Tissue - drug effects | Oligomers | Niacinamide | Arginine | Swine | Vasodilators | Permeability | Insulin | Endothelium | Pharmacology | Stability analysis | Small angle X ray scattering | Arteries | Monomers | Endothelial cells | Vasodilation | Blood flow | X-ray scattering | Absorption | Perfusion | Skin | X ray scattering | Transport | Research Paper
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2018, Volume 20, Issue 7, pp. 1615 - 1622
Journal Article